Program
ensitrelvir
Also written as “S-217622” and “Ensitrelvir”.
Its studies are mostly in COVID-19 · Renal Insufficiency, led by Shionogi.
Furthest: phase 3, since Mar 30, 20225 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Shionogi | 50 open or running | phase 3since Mar 30, 2022 | Mar 30, 2022 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 30, 2022First study: phase 3 study in COVID-19First studyNCT05305547 · 2,093 enrolled · United States, Argentina, Brazil and more
- May 3, 2022Phase 1 study in Renal InsufficiencyNCT05363215 · 32 enrolled · United States
- Jun 3, 2022Phase 1 study in Hepatic ImpairmentNCT05409911 · 25 enrolled · United States
- Jun 6, 2023Phase 3 study in COVID-19NCT05897541 · 3,701 enrolled · United States, Argentina, Japan and more
- Jan 9, 2025Phase 1 study in Healthy Adult Female ParticipantsNCT06775730 · 24 enrolled · United States
TargetBeta
SERPINA1 →read by rule
“This trial will evaluate S-217622 (ensitrelvir), an anti-SARS-CoV2 3C-like protease inhibitor (PI) developed by Shionogi \&;”study text, by rule · the study
Other programs on SERPINA1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| efdoralprin alfa | Sanofi | phase 2 | 2 |
| CTX460rule | crispr-therapeutics | phase 2 | 1 |
| Proteasome Inhibitor SHY-ONC6rule | shy-therapeutics | phase 1 | 1 |
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06775730Healthy Adult Female Participants · United States | 1 | Completed | Apr 3, 2025 | 24 |
| NCT05897541COVID-19 · United States, Argentina, Japan and more | 3 | Completed | Aug 30, 2024 | 3,701 |
| NCT05409911Hepatic Impairment · United States | 1 | Completed | Apr 25, 2023 | 25 |
| NCT05363215Renal Insufficiency · United States | 1 | Completed | Apr 12, 2023 | 32 |
| NCT05305547COVID-19 · United States, Argentina, Brazil and more | 3 | Completed | Jan 7, 2024 | 2,093 |
How it is read
Names in the registry
- “S-217622”, 4 entries
- “Ensitrelvir”, 1 entry
Conditions, from the studies’ own filings
- COVID-19, 2 studies
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.